Blockchain Registration Transaction Record

GeoVax Receives Patent Allowance for Targeted Solid Tumor Therapy

GeoVax Labs, Inc. secures patent allowance for targeted solid tumor therapy, demonstrating a breakthrough in cancer treatment research. The patent covers a triple-combination strategy for treating solid tumors with reduced systemic side effects, highlighting the company's commitment to innovative oncology solutions.

This news highlights a significant advancement in cancer treatment research, showcasing a novel approach for treating solid tumors with reduced systemic side effects. The allowed patent not only strengthens GeoVax's intellectual property position but also opens doors for future developments in targeted therapies for various types of cancer. The synergistic combination of Gedeptin® therapy with radiation represents a promising avenue for improving treatment outcomes and minimizing adverse effects for patients with challenging-to-treat cancers.